Residual abdominal lymphadenopathy after intensive frontline chemoimmunotherapy is associated with inferior outcome independently of minimal residual disease status in chronic lymphocytic leukemia.

Fürstenau, M; Bahlo, J; Fink, A M; Lange, E; Dreger, P; Dreyling, M; Hess, G; Ritgen, M; Kneba, M; Döhner, H; Stilgenbauer, S; Wendtner, C M; Goede, V; Fischer, K; Böttcher, S; Hallek, M; Eichhorst, B

Fürstenau, M; Bahlo, J; Fink, A M; Lange, E; Dreger, P; Dreyling, M; Hess, G; Ritgen, M; Kneba, M; Döhner, H; Stilgenbauer, S; Wendtner, C M; Goede, V; Fischer, K; Böttcher, S; Hallek, M; Eichhorst, B.

Affiliation

Fürstenau M; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne, Cologne, Germany. moritz.fuerstenau@uk-koeln.de.
Bahlo J; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne, Cologne, Germany.
Fink AM; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne, Cologne, Germany.
Lange E; Evangelisches Krankenhaus Hamm, Hamm, Germany.
Dreger P; Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
Dreyling M; Department of Internal Medicine III, University Hospital of the Ludwig Maximilians University Munich, Munich, Germany.
Hess G; Department of Hematology, Medical Oncology and Pneumology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany.
Ritgen M; Department II of Internal Medicine, University of Schleswig-Holstein, Kiel, Germany.
Kneba M; Department II of Internal Medicine, University of Schleswig-Holstein, Kiel, Germany.
Döhner H; Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany.
Stilgenbauer S; Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany.
Wendtner CM; Department of Hematology, Oncology and Rheumatology and José Carreras Center for Immuno and Gene Therapy, Saarland University Medical School, Homburg/Saar, Germany.
Goede V; Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, München Klinik Schwabing, Munich, Germany.
Fischer K; Oncogeriatric Unit, Department of Geriatric Medicine, St. Marien Hospital, Cologne, Germany.
Böttcher S; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne, Cologne, Germany.
Hallek M; Department II of Internal Medicine, University of Schleswig-Holstein, Kiel, Germany.
Eichhorst B; Medical Clinic III, Hematology, Oncology and Palliative Medicine, Rostock University Medical Center, Rostock, Germany.

Leukemia ; 34(3): 924-928, 2020 03.

Article de En | MEDLINE | ID: mdl-31611627

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Leucémie chronique lymphocytaire à cellules B / Maladie résiduelle / Lymphadénopathie / Immunothérapie Type d'étude: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limites: Adult / Aged / Female / Humans / Male / Middle aged Langue: En Journal: Leukemia Sujet du journal: HEMATOLOGIA / NEOPLASIAS Année: 2020 Type de document: Article Pays d'affiliation: Allemagne

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google